Original language | English |
---|---|
Journal | Journal for ImmunoTherapy of Cancer |
Volume | 7 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2019 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. / Verzoni, E.; Cartenì, G.; Cortesi, E.; Giannarelli, D.; De Giglio, A.; Sabbatini, R.; Buti, S.; Rossetti, S.; Cognetti, F.; Rastelli, F.; Sobrero, A.; Turci, D.; Sternberg, C.N.; Porta, C.; Cappuzzo, F.; Tortora, G.; Tassinari, D.; Panni, S.; Pazzola, A.; Surico, G.; Raimondi, A.; De Giorgi, U.; Procopio, G.
In: Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1, 2019.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program
AU - Verzoni, E.
AU - Cartenì, G.
AU - Cortesi, E.
AU - Giannarelli, D.
AU - De Giglio, A.
AU - Sabbatini, R.
AU - Buti, S.
AU - Rossetti, S.
AU - Cognetti, F.
AU - Rastelli, F.
AU - Sobrero, A.
AU - Turci, D.
AU - Sternberg, C.N.
AU - Porta, C.
AU - Cappuzzo, F.
AU - Tortora, G.
AU - Tassinari, D.
AU - Panni, S.
AU - Pazzola, A.
AU - Surico, G.
AU - Raimondi, A.
AU - De Giorgi, U.
AU - Procopio, G.
N1 - Cited By :10 Export Date: 13 February 2020
PY - 2019
Y1 - 2019
U2 - 10.1186/s40425-019-0579-z
DO - 10.1186/s40425-019-0579-z
M3 - Article
VL - 7
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
SN - 2051-1426
IS - 1
ER -